https://www.selleckchem.com/pr....oducts/sabutoclax.ht
The most frequent cause of vision loss from diabetic retinopathy is diabetic macular edema (DME). Earlier clinical trials tried to examine the role of intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IV in DME; they either qualified IVT over IVB or IVB over IVT or did not exhibit a significant difference. This paper aims to compare the efficacy and safety of IVB versus IVT alone or combined IVB+IVT in the treatment of DME. We systematically searched PubMed, CENTRAL, Scopus, Embase, Science Direct, OVID, and Web of Sci
Like
Comment
Share
